Integra LifeSciences (NASDAQ:IART) Stock Price Up 8.5% - Should You Buy?

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) shot up 8.5% on Tuesday . The stock traded as high as $13.11 and last traded at $13.31. 230,143 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 966,247 shares. The stock had previously closed at $12.27.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wells Fargo & Company reduced their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. JMP Securities reduced their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. JPMorgan Chase & Co. reduced their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $18.63.

Integra LifeSciences Stock Down 0.3%

The company has a current ratio of 1.21, a quick ratio of 0.72 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -35.49, a PEG ratio of 0.75 and a beta of 1.15. The firm's 50 day simple moving average is $13.25 and its 200-day simple moving average is $19.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). The firm had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a negative net margin of 1.78% and a positive return on equity of 12.12%. The business's quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 earnings per share. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Integra LifeSciences during the 4th quarter worth $8,967,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Integra LifeSciences by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after purchasing an additional 1,437 shares during the period. GAMMA Investing LLC grew its stake in shares of Integra LifeSciences by 3,595.1% during the 1st quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after purchasing an additional 22,721 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock worth $312,000 after purchasing an additional 913 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Integra LifeSciences by 9.9% during the 4th quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company's stock worth $20,240,000 after purchasing an additional 80,090 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.